BioPorto A/S: USPTO approves BioPorto's NGAL Trauma patent for issuance

United States Patent and Trademark Office (USPTO) has announced, that
BioPorto's NGAL Trauma patent, specifically relating to diagnosing and treating
radiation injury, has been approved for issuance. 

BioPortos' issued patents in the US now comprises BioPorto's NGAL Ratio patent
and issued NGAL patent in-licensed from The Trustees of Columbia University. In
addition to the issued NGAL patents BioPorto has a number pending NGAL patent
applications in the US. Please see BioPorto's Annual Report for a description
of all BioPorto's issued patents and applications. 

Peter Mørch Eriksen, CEO of BioPorto, comments: "We are very pleased that the
NGAL Trauma patent is now approved for issuance in the US after a long period
of waiting for issuance of new diagnostic patens in the US. Along with the
other patents in our IP portfolio it ensures our coverage and we maintain our
position as a major player in the NGAL market." 

For further information, please contact:

Gry Husby Larsen, General Counsel

Peter M. Eriksen, CEO

Telephone [phone], e-mail [e-mail]

About BioPorto

BioPorto Diagnostics A/S is an in-vitro diagnostics company that provides
healthcare professionals in clinical and research settings a range of
diagnostic tests and antibodies. Our pioneering product portfolio includes
assays for underserved disease states such as NGAL for acute kidney injury.
BioPorto has its headquarters in Copenhagen, Denmark and is listed on the
Nasdaq Copenhagen stock exchange.

Attachment:
https://cns.omxgroup.com/cds/DisclosureAttachmentServlet?messageAttachmentId=652564